Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 8/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964210 | 0.87 | RIPK1 (0.46) | RIPK1PKM | |
| SCHEMBL1966131 | 0.82 | KDM1A (0.42) | RIPK1 | |
| SCHEMBL1965544 | 0.81 | RIPK1 (0.47) | RIPK1MAOB | |
| SCHEMBL1965415 | 0.80 | GPR119 (0.36) | RIPK1RORC | |
| SCHEMBL31098564 | 0.79 | RIPK1 (0.63) | RIPK1HTR2AHTR2CSLC6A4MAOB | |
| SCHEMBL1964559 | 0.78 | LMNA (0.44) | SLC6A4MAOBRORC | |
| SCHEMBL1966140 | 0.77 | NPC1 (0.39) | MAOB | |
| SCHEMBL14762235 | 0.75 | SSTR4 (0.52) | RIPK1HTR2AHTR2CSLC6A4MAOB | |
| SCHEMBL1964950 | 0.75 | AKT1 (0.46) | RIPK1HTR2CSLC6A4 | |
| SCHEMBL1966228 | 0.72 | MEN1 (0.41) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2334682-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | Fibrogen, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | HIF1AN, HIF1A, EGLN3 | RIPK1 3787/4885HTR2A 3108/4885HTR2C 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.